SPOTLIGHT: Baxter touts Alzheimer's data


Baxter International's Gammagard intravenous plasma-based treatment demonstrated an ability to improve the mental functions of patients with mild moderate Alzheimer's in a small trial. The trial hit its primary goals in a six-month study involving 24 patients. Secondary endpoints relating to beta-amyloid and anti- amyloid antibody levels were also hit. Recruitment for Phase III begins later in the year. Release

Suggested Articles

A month after scoring $1.6 billion from the U.S. government, Novavax is posting the first human data from its COVID-19 vaccine.

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.